To this end, we used 22Rv1 cells, which are enzalutamide resistant and express AR-V7 [37] and an enzalutamide-resistant PCa cell line (DuCaP EnzaR) that has been previously established in our lab [38]. The gene discussed is AR; the disease is posterior cortical atrophy.